<i>In vitro</i> models of cancer‐associated fibroblast heterogeneity uncover subtype‐specific effects of <scp>CRISPR</scp> perturbationsElysia C. Saputra, Aleksandra Olow, Shamsudheen Karuthedath Vellarikkal et al.|Molecular Oncology|2025Cited by 1
Supplementary Figure S5 from Targeting AEBP1 to Mitigate Protumor Activity of Cancer-Associated Fibroblasts and Increase Therapeutic Efficacy of Anti–PD-1Suchitra Natarajan, Xin Yu, Khoa Nguyen et al.|Unknown|2026Cited by 0
Supplementary Figure S2 from Targeting AEBP1 to Mitigate Protumor Activity of Cancer-Associated Fibroblasts and Increase Therapeutic Efficacy of Anti–PD-1Suchitra Natarajan, Xin Yu, Khoa Nguyen et al.|Unknown|2026Cited by 0
Figure S1 from Targeting AEBP1 to Mitigate Protumor Activity of Cancer-Associated Fibroblasts and Increase Therapeutic Efficacy of Anti–PD-1Suchitra Natarajan, Xin Yu, Khoa Nguyen et al.|Unknown|2026Cited by 0
Supplementary Table S2 from Targeting AEBP1 to Mitigate Protumor Activity of Cancer-Associated Fibroblasts and Increase Therapeutic Efficacy of Anti–PD-1Suchitra Natarajan, Xin Yu, William J. Monis et al.|Unknown|2026Cited by 0